Effect of Candesartan in Alcoholic Liver Fibrosis

Status Completed

Clinical Trial Summary

Background:

Alcohol is one of principal causes of hepatic fibrosis. Although the most effective treatment for alcoholic hepatic fibrosis is abstinence of alcohol consumption, additive treatment to reduce the accumulation of scar tissue can accelerate the improvement of hepatic fibrosis in alcoholic liver disease. The renin-angiotensin system can be an attractive antifibrotic target in liver. Several lines of evidence indicate that overproduction of angiotensin II(ANG II) in chronic liver injury stimulates the activation of hepatic stellate cells(HSCs) attributed to fibrogenesis. Additionally, the antifibrotic effect of ANG II blocking agent has been shown in various animal models and hepatitis C patients. Hence, drugs that inhibit the renin-angiotensin system have promise in ameliorating hepatic fibrosis in chronic liver injury. However, no study has been conducted in patients with alcoholic liver disease to evaluate the effect ANG II type I receptor blocking agent on hepatic fibrosis.

Aim:

This study aimed to investigate the safety and the efficacy of chronic administration of candesartan to hepatic fibrosis patients with alcoholic liver disease.

Methods

1) Patients with liver fibrosis(F2) were randomized to receive either the angiotensin receptor blocker(ARB), candesartan(8 mg/day) with ursodeoxycholic acid(UDCA)(600 mg/day)(n = 42), or UDCA alone(n = 43) as control for 6 months. 2)All enrolled patients underwent liver biopsies twice for measurement of fibrosis score, area of fibrosis and alpha-smooth muscle actin(SMA) positive and hydroxyproline. 3) Transforming growth factor-beta1(TGF-beta1), collagen-1, angiotensin II type I receptor(AT1-R), tissue inhibitor of metalloproteinase-1(TIMP-1), Rac1 and p22phox which represent oxidant stress were also measured by real-time RT-PCR before and after 6 months of therapy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00990639
Study type	Interventional
Source	Yonsei University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 2005
Completion date	March 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00708617` - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease	N/A
Recruiting	`NCT04106518` - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting	`NCT04666402` - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting	`NCT02331745` - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure	Phase 4
Completed	`NCT01501162` - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease	Phase 4
Recruiting	`NCT05895890` - French National MICMAF Cohort
Completed	`NCT04557774` - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting	`NCT03267069` - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting	`NCT03295812` - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)	N/A
Recruiting	`NCT05855031` - The Liver Care Trial	N/A
Not yet recruiting	`NCT03503708` - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease	N/A
Completed	`NCT02796469` - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT02140294` - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease	N/A
Recruiting	`NCT03209791` - Ethanol Induces Skeletal Muscle Autophagy
Recruiting	`NCT04400604` - Study of Alcohol-related Liver Disease in Europe
Recruiting	`NCT04736966` - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Phase 1
Completed	`NCT03402256` - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients	N/A
Completed	`NCT01711125` - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease	Phase 3
Active, not recruiting	`NCT03863730` - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota	N/A
Not yet recruiting	`NCT06307964` - Intra-Hepatic Microbiota in Alcoholic Hepatitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.